跳至主要内容
临床试验/NCT04144270
NCT04144270Unknown不适用

The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

Rigshospitalet, Denmark1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2019年11月18日最近更新:
适应症

试验速览

阶段
不适用
入组人数
30
试验地点
1
主要终点
Muscle mass

研究概览

简要总结

This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent
  • Age ≥ 18 år
  • Histologically verified cancer of the renal pelvis, ureter, bladder or urethra regardless of type of histology
  • ECOG performance status 0 - 3
  • Meet the requirements for receiving oncological treatment (neoadjuvant chemotherapy for localized disease, chemotherapy or immunotherapy for disseminated disease).

排除标准

  • Age < 18

结局指标

主要结局

Muscle mass

时间窗: Up to 36 months

We will describe if muscle mass at baseline is correlated to completion of planned systemic oncological treatment

次要结局

  • Muscle strength(Up to 36 months)
  • Muscle mass changes during systemic oncological treatment(Up to 36 months)
  • Muscle strength changes during systemic oncological treatment(Up to 36 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lise Hoej Omland

MD

Rigshospitalet, Denmark

研究点 (1)

Loading locations...

相似试验

The Importance of Muscle Function in Patients With... | 临床试验